Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study
Switching to B/F/TAF from DTG/ABC/3TC was associated with continued high rates of virologic suppression up to week 168, with no treatment-emergent resistance. B/F/TAF was well tolerated throughout the study period.
Authors
- Indira Brar (ORCID: https://orcid.org/0000-0002-0568-6457)
- Paul Benson
- Mezgebe Berhe (ORCID: https://orcid.org/0000-0002-7287-567X)
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- Kristen Andreatta
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Peter Ruane (ORCID: https://orcid.org/0000-0002-7170-9928)
- Hui Liu (ORCID: https://orcid.org/0009-0002-1407-0117)
- Cynthia Brinson
- Keith Henry (ORCID: https://orcid.org/0000-0003-3515-7748)
Institutions
- Midway University (US)
- Henry Ford Hospital (US)
- Infectious Disease Consultants (US)
- Gilead Sciences (United States) (US)
- Ruane Medical (US)
- Hennepin Healthcare Research Institute (US)
Publication Details
- Journal
- Medicine
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1097/md.0000000000041482
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79